Iteos Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
iTeos Therapeutics Chief Operating Officer Matthew Call disposed of all common stock and derivative securities following the company's merger with Concentra Biosciences.
iTeos Therapeutics CEO Michel Detheux disposed of common stock and stock options following the company's merger with Concentra Biosciences.
iTeos Therapeutics Director David K Lee disposed of all stock options as part of the company's merger with Concentra Biosciences.
iTeos Therapeutics' Chief Medical Officer, David Feltquate, disposed of 47,000 restricted stock units as part of the company's merger with Concentra Biosciences.
iTeos Therapeutics CFO Matthew Gall disposed of all his beneficial ownership in the company following its acquisition by Concentra Biosciences for $10.047 per share plus a CVR.
iTeos Therapeutics Chief Scientific Officer Yvonne McGrath reported the disposition of common stock and stock options following the company's merger with Concentra Biosciences.
Ann D. Rhoads, a director at iTeos Therapeutics, Inc., disposed of 27,178 stock options following the company's merger with Concentra Biosciences.
iTeos Therapeutics Director David Hallal disposed of stock options as part of the company's merger with Concentra Biosciences.
iTeos Therapeutics, Inc. CEO Michel Detheux engaged in pre-planned transactions, exercising stock options and selling a portion of the acquired shares for profit, while also increasing his total beneficial ownership in the company.
Form 4: iTeos Therapeutics CEO Michel Detheux Executes Pre-Planned Stock Option Exercises and Share Sales
iTeos Therapeutics CEO Michel Detheux executed a series of pre-planned transactions, exercising stock options at $4.30 and subsequently selling shares at weighted average prices between $10.10 and $10.21, both directly and indirectly through a related entity.
Form 4: iTeos Therapeutics Director Exercises and Sells Over 114,000 Shares Under Pre-Arranged Trading Plan
David Hallal, a Director at iTeos Therapeutics, Inc., executed a series of option exercises and subsequent sales of 114,682 common shares between June 4 and June 6, 2025, as part of a Rule 10b5-1 trading plan.
EcoR1 Capital, a significant shareholder of iTeos Therapeutics, has increased its holdings through multiple open market purchases of common stock.
Ansbert Gadicke, a managing partner at MPM BioImpact LLC, reports the sale of 1,031,931 shares of iTeos Therapeutics, Inc. at an average price of $8.06.
MPM BioVentures 2018, L.P., a former 10% owner of iTeos Therapeutics, Inc., reports the sale of 630,191 shares of common stock at a weighted average price of $8.06.
MPM BioVentures 2014, L.P. and related entities sold 630,191 shares of iTeos Therapeutics (ITOS) at an average price of $8.06 on May 13, 2025.
Director Timothy Van Hauwermeiren exercised stock options for 22,346 shares of Iteos Therapeutics common stock at a price of $4.3 per share.
Michel Detheux, CEO of iTeos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a Form 4 filing with the SEC.
Matthew Gall, CFO of Iteos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a Form 4 filing with the SEC.
Form 4: Iteos Therapeutics Executive Yvonne McGrath Receives Stock Options and Restricted Stock Units
Yvonne McGrath, Chief Scientific Officer of Iteos Therapeutics, was granted stock options and restricted stock units (RSUs) on March 7, 2025, according to a recent SEC filing.
Matthew Call, Chief Operating Officer of Iteos Therapeutics, acquired 145,000 stock options and 24,000 restricted stock units on March 7, 2025.
David Feltquate, Chief Medical Officer of iTeos Therapeutics, was granted 47,000 restricted stock units (RSUs) that will vest on December 6, 2026.
iTeos Therapeutics' Chief Financial Officer, Matthew Gall, purchased 5,000 shares of common stock at a price of $7.727 per share on November 19, 2024.
CEO of iTeos Therapeutics, Michel Detheux, transferred stock options to MG3A, a Belgian partnership.
David Feltquate, Chief Medical Officer of iTeos Therapeutics, received 350,000 stock options on August 1, 2024, according to a Form 4 filing with the SEC.
Director Tony W. Ho of iTeos Therapeutics, Inc. reports acquisition of stock options.
Director Timothy Van Hauwermeiren acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Director David K. Lee acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Director Aaron I. Davis acquired stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Director David Hallal acquired stock options for Iteos Therapeutics, Inc. on June 11, 2024.
Jill DeSimone, a director of Iteos Therapeutics, acquired 24,200 stock options on June 11, 2024, at an exercise price of $16.32.